WO1999040921A3 - Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors - Google Patents

Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors Download PDF

Info

Publication number
WO1999040921A3
WO1999040921A3 PCT/US1999/003318 US9903318W WO9940921A3 WO 1999040921 A3 WO1999040921 A3 WO 1999040921A3 US 9903318 W US9903318 W US 9903318W WO 9940921 A3 WO9940921 A3 WO 9940921A3
Authority
WO
WIPO (PCT)
Prior art keywords
reverse transcriptase
transcriptase inhibitors
oral liquid
hiv reverse
benzoxazinones
Prior art date
Application number
PCT/US1999/003318
Other languages
French (fr)
Other versions
WO1999040921A2 (en
Inventor
Surendra M Bahal
Michael B Maurin
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE69934097T priority Critical patent/DE69934097T2/en
Priority to JP2000531173A priority patent/JP2002502878A/en
Priority to EP99907077A priority patent/EP1054674B1/en
Priority to CA002319609A priority patent/CA2319609C/en
Priority to IL13776399A priority patent/IL137763A0/en
Priority to NZ506579A priority patent/NZ506579A/en
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Priority to AU26827/99A priority patent/AU745008C/en
Priority to BRPI9908132A priority patent/BRPI9908132B8/en
Priority to BRPI9908132A priority patent/BRPI9908132C1/en
Publication of WO1999040921A2 publication Critical patent/WO1999040921A2/en
Publication of WO1999040921A3 publication Critical patent/WO1999040921A3/en
Priority to HK01101680A priority patent/HK1030749A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A palatable oral liquid pharmaceutical composition of benzoxazinone compounds useful as HIV reverse transcriptase inhibitors comprising the benzoxazinone active ingredient in a liquid vehicle comprising medium chain fatty acid triglycerides. Other formulating agents such as sweetening agents, lecithin suspending agents, etc. may be optionally added.
PCT/US1999/003318 1998-02-17 1999-02-17 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors WO1999040921A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2000531173A JP2002502878A (en) 1998-02-17 1999-02-17 Oral liquid formulations of benzoxazinone HIV reverse transcriptase inhibitors
EP99907077A EP1054674B1 (en) 1998-02-17 1999-02-17 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
CA002319609A CA2319609C (en) 1998-02-17 1999-02-17 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
IL13776399A IL137763A0 (en) 1998-02-17 1999-02-17 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
NZ506579A NZ506579A (en) 1998-02-17 1999-02-17 Palatable oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
DE69934097T DE69934097T2 (en) 1998-02-17 1999-02-17 LIQUID ORAL FORMULATIONS OF BENZOXAZINONES CONTAINING HIV REVERSE TRANSCRIPTASE INHIBITORS
AU26827/99A AU745008C (en) 1998-02-17 1999-02-17 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
BRPI9908132A BRPI9908132B8 (en) 1998-02-17 1999-02-17 liquid pharmaceutical composition for oral administration
BRPI9908132A BRPI9908132C1 (en) 1998-02-17 1999-02-17 liquid pharmaceutical composition for oral administration
HK01101680A HK1030749A1 (en) 1998-02-17 2001-03-08 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7488198P 1998-02-17 1998-02-17
US60/074,881 1998-02-17

Publications (2)

Publication Number Publication Date
WO1999040921A2 WO1999040921A2 (en) 1999-08-19
WO1999040921A3 true WO1999040921A3 (en) 1999-11-04

Family

ID=22122226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003318 WO1999040921A2 (en) 1998-02-17 1999-02-17 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors

Country Status (19)

Country Link
US (1) US6235733B1 (en)
EP (1) EP1054674B1 (en)
JP (1) JP2002502878A (en)
CN (1) CN1170541C (en)
AR (1) AR018092A1 (en)
AT (1) ATE345802T1 (en)
AU (1) AU745008C (en)
BR (2) BRPI9908132B8 (en)
CA (1) CA2319609C (en)
DE (1) DE69934097T2 (en)
ES (1) ES2277429T3 (en)
HK (1) HK1030749A1 (en)
HR (1) HRP990049A2 (en)
IL (1) IL137763A0 (en)
MY (1) MY139034A (en)
NZ (1) NZ506579A (en)
TW (1) TW528596B (en)
WO (1) WO1999040921A2 (en)
ZA (1) ZA99981B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3525792A4 (en) * 2016-10-11 2020-04-22 Aucta Pharmaceuticals Powder for oral suspension containing lamotrigine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
WO1997040833A1 (en) * 1996-05-02 1997-11-06 Merck & Co., Inc. Hiv protease inhibitors useful for the treatment of aids
WO1998014436A1 (en) * 1996-10-02 1998-04-09 Dupont Pharmaceuticals Company 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as hiv reverse transcriptase inhibitors and intermediates and processes for making the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2095926T5 (en) * 1990-11-02 2001-02-16 Novartis Ag CYCLOSPORINS
US5494936A (en) * 1992-04-27 1996-02-27 Vyrex Corporation Delivery formulation for probucol
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
WO1997040833A1 (en) * 1996-05-02 1997-11-06 Merck & Co., Inc. Hiv protease inhibitors useful for the treatment of aids
WO1998014436A1 (en) * 1996-10-02 1998-04-09 Dupont Pharmaceuticals Company 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as hiv reverse transcriptase inhibitors and intermediates and processes for making the same

Also Published As

Publication number Publication date
BRPI9908132B1 (en) 2015-07-14
BRPI9908132B8 (en) 2016-11-16
AU2682799A (en) 1999-08-30
CN1291098A (en) 2001-04-11
TW528596B (en) 2003-04-21
AR018092A1 (en) 2001-10-31
CA2319609C (en) 2007-09-18
HK1030749A1 (en) 2001-05-18
DE69934097D1 (en) 2007-01-04
CN1170541C (en) 2004-10-13
ZA99981B (en) 2000-08-08
BRPI9908132C1 (en) 2021-05-25
CA2319609A1 (en) 1999-08-19
BR9908132A (en) 2000-12-05
ATE345802T1 (en) 2006-12-15
AU745008B2 (en) 2002-03-07
ES2277429T3 (en) 2007-07-01
HRP990049A2 (en) 1999-12-31
EP1054674A2 (en) 2000-11-29
MY139034A (en) 2009-08-28
JP2002502878A (en) 2002-01-29
WO1999040921A2 (en) 1999-08-19
DE69934097T2 (en) 2007-06-28
NZ506579A (en) 2002-11-26
EP1054674B1 (en) 2006-11-22
AU745008C (en) 2003-03-27
IL137763A0 (en) 2001-10-31
US6235733B1 (en) 2001-05-22

Similar Documents

Publication Publication Date Title
CA2338358A1 (en) Compounds and compositions for delivering active agents
CA2320182A1 (en) Compositions containing organic compounds
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
SI1526839T1 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
DE69718668T2 (en) LIQUID COMPOSITION, INCLUDING HIV PROTEASE INHIBITORS AND C12-C18 FATTY ACID
WO2001041737A3 (en) Solid oral dosage form
WO2000074677A3 (en) Improved pharmaceutical formulations
WO2005053652A8 (en) Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2003074043A1 (en) Body temperature elevating agents
EP1295879A4 (en) Medicinal compositions containing propenone derivatives
CA2338794A1 (en) New oral formulation for 5-ht4 agonists or antagonists
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
AU2001232238A1 (en) Anti-acid-fast bacterial agents containing pyridonecarboxylic acids as the active ingredient
HK1120213A1 (en) Improved hiv protease inhibitors pharmaceutical formulations
WO1999040921A3 (en) Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
WO1999047172A3 (en) Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
IL134930A0 (en) Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing the same
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration
PT1005275E (en) INHIBITOR AND PROPHYLACTIC FORMULATION
WO2000007580A3 (en) Pharmaceutical compositions against autoimmune diseases
ZA99978B (en) Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors.
WO2001070216A3 (en) Diphenyl ketoaldehyde derivatives with anti-hiv activity
TH57976A (en) Eplyrenone components
TH57976B (en) Eplyrenone components

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99802950.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN CZ EE HU IL JP KR LT LV MX NO NZ PL RO SG SI SK UA VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN CZ EE HU IL JP KR LT LV MX NO NZ PL RO SG SI SK UA VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 26827/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999907077

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2319609

Country of ref document: CA

Ref document number: 2319609

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/007579

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 137763

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2000 531173

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 506579

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1999907077

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 26827/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999907077

Country of ref document: EP